Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study
4 affiliations
- 1Department of Oncology Georgetown University Medical Center Washington, DC United States
- 2Department of Biology College of Arts and Sciences Georgetown University Washington, DC United States
- 3National Center for Human Factors in Healthcare MedStar Health Research Institute Washington, DC United States
- 4Division of Endocrinology Georgetown University Washington, DC United States
Abstract
Background: Thyroid cancer is often labeled a “good cancer” due to high survival rates. However, many patients diagnosed with differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI) experience short- and long-term symptoms as a result of treatment. These include salivary dysfunction, dry mouth, dry eyes, and nausea. Despite these challenges, patients report limited knowledge and unmet informational needs regarding RAI symptoms and symptom management. Evidence-based, patient-centered education to support symptom management during DTC survivorship is needed. Our team developed Radioactive Iodine Support (RAI Support), a prototype of a 4-week web-based intervention for RAI symptom management among survivors of DTC.
Objective: This study aimed to evaluate the usability of the RAI Support intervention among survivors of DTC who completed RAI treatment and assess preliminary effect sizes of change in RAI symptom burden, self-efficacy for managing chronic symptoms, informational needs, global physical and mental health, and health-related quality of life (HRQOL).
Methods: We conducted a longitudinal usability testing study with 8 participants over a 4-week period. At baseline (T1), participants completed an online survey and a 90-minute virtual usability testing session. During usability testing sessions, study staff used a think-aloud protocol to elicit feedback on the content, language, and visual appeal of the prototype across 5 tasks. Participants also completed the System Usability Scale (SUS). Participants were encouraged to continue using the intervention over the 4-week period, during which use data were recorded. A follow-up after assessment (T2) was completed at the end of the 4-week period of home use. Survey outcomes included RAI symptom burden, self-efficacy for managing chronic symptoms, informational needs, global physical and mental health, and HRQOL.
Results: Among the 8 survivors of DTC who had undergone RAI treatment (age: mean 45, SD 8.2 years), the mean SUS score was 88.1 (SD 8.7), indicating above-average usability. All participants effectively completed each task, with ease of use ranging from 100% to 87.5% and error rates ranging from 0% to 25%. Preliminary r effect size signals of change were found for improved self-efficacy, global mental health, and HRQOL (r values ranged from 0.31 to 0.45).
Conclusions: Survivors of DTC reported above-average usability of the RAI Support prototype and completed each task successfully. Variability in error rates and ease of use suggests that refinements are needed to further optimize usability and patient engagement. RAI Support also shows preliminary promise in improving self-efficacy for symptom management, global mental health, and HRQOL among survivors of DTC. Findings support future pilot testing.
Related
- A theory-driven mobile application based on iterative collaborative design principles to support depression self-management in older adults: development and usability evaluation of “Mind Garden”
- Effects of Carton Redesign following Package Insert Digitization on Usability and Carbon Footprint of Vaccine Vials
- Best Practice and Management of Sexual Dysfunction Following Diagnosis and Treatment of Gynecological Cancer.
- Development and usability testing of a machine learning clinical decision support tool for suggesting etiologies and treatment of clinical deterioration
- Patients' experience of using online interventions for the management of late effects following completion of cancer treatment-protocol for a qualitative systematic review.
BibTeX
@article{carr2026symptom,
title = {{Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study}},
author = {Alaina Carr and Angela M Jenkins and Valeria Gómez and Janine Alexandria Lorenzo and Ryan Moclair and James Pocchia and Devansh Gandhi and Kristen Miller and Kristi D Graves and Jacqueline Jonklaas},
journal = {JMIR Cancer},
year = {2026},
month = oct,
doi = {10.2196/84151},
url = {https://doi.org/10.2196/84151},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Symptom Management Following Radioactive Iodine Treatment in Adults With Thyroid Cancer: Usability Evaluation and Proof-of-Concept Study
AU - Alaina Carr
AU - Angela M Jenkins
AU - Valeria Gómez
AU - Janine Alexandria Lorenzo
AU - Ryan Moclair
AU - James Pocchia
AU - Devansh Gandhi
AU - Kristen Miller
AU - Kristi D Graves
AU - Jacqueline Jonklaas
PY - 2026
DA - 2026/10/13
JO - JMIR Cancer
DO - 10.2196/84151
UR - https://doi.org/10.2196/84151
AB - Background: Thyroid cancer is often labeled a “good cancer” due to high survival rates. However, many patients diagnosed with differentiated thyroid cancer (DTC) treated with radioactive iodine (RAI) experience short- and long-term symptoms as a result of treatment. These include salivary dysfunction, dry mouth, dry eyes, and nausea. Despite these challenges, patients report limited knowledge and unmet informational needs regarding RAI symptoms and symptom management. Evidence-based, patient-centered education to support symptom management during DTC survivorship is needed. Our team developed Radioactive Iodine Support (RAI Support), a prototype of a 4-week web-based intervention for RAI symptom management among survivors of DTC. Objective: This study aimed to evaluate the usability of the RAI Support intervention among survivors of DTC who completed RAI treatment and assess preliminary effect sizes of change in RAI symptom burden, self-efficacy for managing chronic symptoms, informational needs, global physical and mental health, and health-related quality of life (HRQOL). Methods: We conducted a longitudinal usability testing study with 8 participants over a 4-week period. At baseline (T1), participants completed an online survey and a 90-minute virtual usability testing session. During usability testing sessions, study staff used a think-aloud protocol to elicit feedback on the content, language, and visual appeal of the prototype across 5 tasks. Participants also completed the System Usability Scale (SUS). Participants were encouraged to continue using the intervention over the 4-week period, during which use data were recorded. A follow-up after assessment (T2) was completed at the end of the 4-week period of home use. Survey outcomes included RAI symptom burden, self-efficacy for managing chronic symptoms, informational needs, global physical and mental health, and HRQOL. Results: Among the 8 survivors of DTC who had undergone RAI treatment (age: mean 45, SD 8.2 years), the mean SUS score was 88.1 (SD 8.7), indicating above-average usability. All participants effectively completed each task, with ease of use ranging from 100% to 87.5% and error rates ranging from 0% to 25%. Preliminary r effect size signals of change were found for improved self-efficacy, global mental health, and HRQOL (r values ranged from 0.31 to 0.45). Conclusions: Survivors of DTC reported above-average usability of the RAI Support prototype and completed each task successfully. Variability in error rates and ease of use suggests that refinements are needed to further optimize usability and patient engagement. RAI Support also shows preliminary promise in improving self-efficacy for symptom management, global mental health, and HRQOL among survivors of DTC. Findings support future pilot testing.
SN - 2369-1999
ER -